COMP <GO>
TDOC vs JNJ // GROSS PROFIT MARGIN
Teladoc Health Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: TDOC 2
— JNJ 9
▲ GROSS PROFIT MARGIN LEADER: JNJ
LAST: $8.51 (-2.52%) • MKT CAP: $1.59B
gross-margins
41.00%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
gross-margins
67.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TDOC VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TDOC | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -17.00% | 25.50% | -42.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 18.00% | 2.97% | +15.03 | TDOC | /fcf-yield <GO> |
| Operating Margin | -10.40% | 34.70% | -45.10 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -7.90% | 28.50% | -36.40 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | -1.50% | 6.00% | -7.50 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 5.59 | -5.14 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 7.20% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 77.7 | 60.4 | +17.34 | TDOC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.08 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.0x | 23.0x | +9.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.59B | $662.49B | -$660.91B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TDOC REV | JNJ REV | TDOC GROSS % | JNJ GROSS % | TDOC FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.53B | $94.19B | 44.0% | 67.9% | $285.5M | $19.70B |
| FY 2024 | $2.57B | $88.82B | 44.0% | 69.1% | $282.9M | $19.84B |
| FY 2023 | $2.60B | $85.16B | 44.0% | 44.0% | $232.9M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TDOC // BETA 1.08
JNJ // BETA 1.08